p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.

Interactions between the p53 and PI3K/AKT pathways play a significant role in the determination of cell death/survival. In benign cells these pathways are interrelated through the transcriptional regulation of PTEN by p53, which is required for p53-mediated apoptosis. PTEN exerts its effects by decreasing the phosphorylated AKT fraction, thereby diminishing prosurvival activities. However, the link between these pathways in cancer is not known. In this study, PIK3CA, encoding the p110alpha catalytic subunit of PI3K, is identified as an oncogene involved in upper aerodigestive tract (UADT) carcinomas. Simultaneous abnormalities in both pathways are rare in primary tumors, suggesting that amplification of PIK3CA and mutation of p53 are mutually exclusive events and either event is able to promote a malignant phenotype. Moreover, the negative effect of p53 induction on cell survival involves the transcriptional inhibition of PIK3CA that is independent of PTEN activity, as PTEN is not expressed in the primary tumors. Conversely, constitutive activation of PIK3CA results in resistance to p53-related apoptosis in PTEN deficient cells. Thus, p53 regulates cell survival by inhibiting the PI3K/AKT prosurvival signal independent of PTEN in epithelial tumors. This inhibition is required for p53-mediated apoptosis in malignant cells.

[1]  J. Shah,et al.  Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. , 2001, Cancer research.

[2]  N. Zhao,et al.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Inazawa,et al.  Comparative genomic hybridization of squamous cell carcinoma of the esophagus: The possible involvement of the DP1 gene in the 13q34 amplicon , 1999, Genes, chromosomes & cancer.

[4]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[5]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.

[6]  D. K. Bhuyan,et al.  Growth factor receptor gene and protein expressions in the human lens , 2000, Mechanisms of Ageing and Development.

[7]  F. McCormick,et al.  Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis* , 1999, The Journal of Biological Chemistry.

[8]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[10]  F. Quelle,et al.  DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. , 2001, Blood.

[11]  G. Thomas,et al.  P53 gene alterations in human tumors: perspectives for cancer control. , 1997, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[12]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[13]  N. Hacker,et al.  Anti–sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell–adhesion and tumorigenicity in ovarian cancer cells , 2000, International journal of cancer.

[14]  A. J. Levine.  The p53 tumor-suppressor gene. , 1992, The New England journal of medicine.

[15]  L. Pirola,et al.  Structure and function of phosphoinositide 3-kinases. , 1998, Biochimica et biophysica acta.

[16]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[17]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[19]  A. Stoffel,et al.  Chromosome 18 breakpoint in t(11;18)(q21;q21) translocation associated with MALT lymphoma is proximal to BCL2 and distal to DCC , 1999, Genes, chromosomes & cancer.

[20]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[21]  S. Knuutila,et al.  DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma , 1998, Genes, chromosomes & cancer.

[22]  S. Knuutila,et al.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.

[23]  W. Sellers,et al.  Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[25]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[26]  B D Kahan,et al.  Computerized quantitation of immunosuppressive synergy for clinical protocol design. , 1994, Transplantation proceedings.